GLSI تصريحات هيئة الأوراق المالية والبورصات - Greenwich LifeSciences, Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

1799788

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Greenwich LifeSciences, Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, IN
July 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 19, 2025 Greenwich LifeScienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 19, 2025 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commissi
July 24, 2025	EX-16.1	Letter from RBSM LLP to the Securities and Exchange Commission dated July 22, 2025. Exhibit 16.1 7915 FM 1960 West, Ste. 220 Houston, TX 77070 July 22, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-7561 Dear Sirs: We have read Greenwich LifeSciences, Inc.’s statements included under Item 4.01 of its Form 8-K dated July 24, 2025, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation
May 20, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, I
May 15, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐
April 15, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from  to Commission File Number: 001-39555 GREENWICH LIFESC
April 15, 2025	EX-19.1	Greenwich LifeSciences, Inc. Insider Trading Policy Exhibit 19.1 GREENWICH LIFESCIENCES, INC. INSIDER TRADING COMPLIANCE PROGRAM In order to take an active role in the prevention of insider trading violations by its officers, directors, employees and other related individuals, the Board of Directors (the “Board”) of Greenwich LifeSciences, Inc. (the “Company”) has adopted the policies and procedures described in this Memorandum. I. Adoption of Insi
March 31, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR
December 20, 2024	S-8	As filed with the Securities and Exchange Commission on December 20, 2024 As filed with the Securities and Exchange Commission on December 20, 2024 Registration No.
December 20, 2024	EX-FILING FEES	Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) GREENWICH LIFESCIENCES, INC.
December 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 19, 2024 Greenwich LifeSc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 19, 2024 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCE
November 1, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
November 1, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
October 15, 2024	CORRESP	Greenwich LifeSciences, Inc. 3992 Bluebonnet Dr., Building 14 Stafford, TX 77477 Greenwich LifeSciences, Inc. 3992 Bluebonnet Dr., Building 14 Stafford, TX 77477 October 15, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Greenwich LifeSciences, Inc. Form S-3 Registration Statement Filed October 7, 2024 File No. 333-282533 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and
October 7, 2024	S-3	As filed with the U.S. Securities and Exchange Commission on October 7, 2024 As filed with the U.S. Securities and Exchange Commission on October 7, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5473709 (State or other jurisdiction IRS Employer of incorporation or
October 7, 2024	EX-4.3	Form of Senior Indenture Exhibit 4.3 GREENWICH LIFESCIENCES, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificat
October 7, 2024	EX-1.2	At The Market Offering Agreement, dated as of October 7, 2024, between the Registrant and H.C. Wainwright & Co., LLC Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT October 7, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Greenwich LifeSciences, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used
October 7, 2024	EX-4.4	Form of Subordinated Indenture Exhibit 4.4 GREENWICH LIFESCIENCES, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Ce
October 7, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) GREENWICH LIFESCIENCES, INC.
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, IN
June 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 13, 2024 Greenwich LifeScienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 13, 2024 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commissi
June 17, 2024	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 13th, 2024 (the “Effective Date”), between Greenwich LifeSciences, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (each, including its successors and assigns, a “Purchaser”). WHEREAS, subject to the terms and conditions set fo
May 20, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, I
May 15, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐
April 15, 2024	EX-97.1	Clawback Policy Exhibit 97 Greenwich LifeSciences, Inc. CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this
April 15, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from  to Commission File Number: 001-39555 GREENWICH LIFESC
April 1, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR
February 20, 2024	EX-16.1	Letter from MaloneBailey LLP to the Securities and Exchange Commission dated February 16, 2024. Exhibit 16.1 February 16, 2024 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 We have read the statements under Item 4.01 of the Current Report on Form 8-K of Greenwich LifeSciences, Inc. to be filed with the Securities and Exchange Commission on or about February 20, 2024. We agree with all statements pertaining to us. We have no basis on which to agree or disagre
February 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 Greenwich LifeSc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
February 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 Greenwich LifeSc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
February 14, 2024	EX-99.1	Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01 Exhibit 99.1 Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01 STAFFORD, Texas, February 14, 2024 — (Globe Newswire) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, to
December 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2023 Greenwich LifeSc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2023 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
October 25, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
October 25, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
October 19, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCE
August 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, IN
August 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ T
May 22, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, I
May 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐
April 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2023 Greenwich LifeScien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2023 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commiss
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39555 GREENWICH LIFESCI
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 13, 2023 Greenwich LifeScien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 13, 2023 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commiss
December 9, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 9, 2022 Greenwich LifeSci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 9, 2022 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commi
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCE
October 19, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
October 19, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, IN
July 12, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2022 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commissi
July 12, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2022 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commissi
July 12, 2022	EX-99.1	Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed Exhibit 99.1 July 12, 2022 Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed STAFFORD, Texas?(Business Wire)? Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the ?Company?), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitt
July 12, 2022	424B5	Up to $100,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-263855 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 6, 2022) Up to $100,000,000 Shares of Common Stock We have entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the a
July 12, 2022	EX-1.1	Open Market Sale Agreement, dated July 12, 2022 by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 to Form 8-K filed on July 12, 2022) EX-1.1 2 ex1-1.htm Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM July 12, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Greenwich LifeSciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of
July 11, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2022 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commissi
July 5, 2022	S-8	As filed with the Securities and Exchange Commission on July 5, 2022 As filed with the Securities and Exchange Commission on July 5, 2022 Registration No.
July 5, 2022	EX-FILING FEES	Filing Fee Tables EX-FILING FEES 4 ex107.htm Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) GREENWICH LIFESCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration F
June 24, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-395
June 22, 2022	SC 13G	GLSI / Greenwich Lifesciences Inc / Weiner Michael Guy Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Greenwich LifeSciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of
May 20, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, I
May 17, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR ?
April 4, 2022	CORRESP	Greenwich LifeSciences, Inc. 3992 Bluebonnet Dr., Building 14 Stafford, TX 77477 Greenwich LifeSciences, Inc. 3992 Bluebonnet Dr., Building 14 Stafford, TX 77477 April 4, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Gary Guttenberg Re: Greenwich LifeSciences, Inc. Amendment No. 1 to Form S-3 Registration Statement Filed April 1, 2022 File No. 333-263855 Ladies and Gentlemen: Pursuant to Rule 461 of the Gen
April 1, 2022	S-3/A	As filed with the U.S. Securities and Exchange Commission on April 1, 2022 As filed with the U.S. Securities and Exchange Commission on April 1, 2022 Registration No. 333-263855 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5473709 (State or other jurisdiction IRS Employ
March 25, 2022	EX-4.4	Form of Subordinated Indenture Exhibit 4.4 GREENWICH LIFESCIENCES, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Ce
March 25, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) GREENWICH LIFESCIENCES, INC.
March 25, 2022	EX-4.3	Form of Senior Indenture Exhibit 4.3 GREENWICH LIFESCIENCES, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee?s Certificat
March 25, 2022	S-3	Power of Attorney (included on signature page hereto). As filed with the U.S. Securities and Exchange Commission on March 25, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5473709 (State or other jurisdiction IRS Employer of incorporation or o
March 21, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39555 GREENWICH LIFESCI
December 15, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2021 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
December 13, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 9, 2021 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commi
December 13, 2021	EX-99.1	December 9, 2021 Exhibit 99.1 December 9, 2021 Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology ? Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence ? A positive baseline immune response to GP2 in 22
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCE
November 10, 2021	EX-99.1	Corporate Presentation of Greenwich LifeSciences, Inc. Exhibit 99.1
November 10, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2021 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commi
November 10, 2021	EX-99.2	November 9, 2021 Exhibit 99.2 November 9, 2021 Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts STAFFORD, Texas-(Business Wire) - Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the ?Company?), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provides i
October 20, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
October 19, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, IN
June 10, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2021 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commissio
June 10, 2021	EX-99.1	June 8, 2021 Exhibit 99.1 June 8, 2021 Greenwich LifeSciences Set to Join Russell 2000? Index STAFFORD, Texas?(Business Wire)? Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the ?Company?), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it is set to join the
June 9, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 7, 2021 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commissio
June 9, 2021	EX-99.1	Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated Exhibit 99.1 June 7, 2021 Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated ? Poster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer clinical trial.
May 20, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCE
May 17, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-39555 NOTIFICATION OF LATE FILING [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on F
April 20, 2021	EX-99.1	Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization Exhibit 99.1 April 19, 2021 Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization - Previously led partnering transactions and strategic analyses for multiple companies, including Roche, Pfizer, and Novartis - Dr. Fischette will focus on out-licensing the Company’s lead drug candidate for recurring breast cancer, GP2, and bu
April 20, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2021 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commiss
April 15, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 14, 2021 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commiss
April 15, 2021	EX-99.1	Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting Exhibit 99.1 April 14, 2021 Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting ? The GP2 Phase III clinical trial design was presented in a poster during the 2021 American Association for Cancer Research (AACR) Annual Meeting, introduced by the Global Principal Investigator, Professor Mothaffar F. Rimawi of Baylor College of Medicine. ? T
April 13, 2021	EX-99.1	Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up Exhibit 99.1 April 9, 2021 Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up ? Abstract published today at the American Association for Cancer Research (AACR) Annual Meeting shows the GP2 final 5 year immune response data from the Phase IIb clinical trial. ? Poster showing immune
April 13, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2021 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commissi
April 13, 2021	EX-99.2	Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer Exhibit 99.2 April 10, 2021 Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer ? Poster published today at the 2021 American Association for Cancer Research (AACR) Annual Meeting shows the GP2 final 5 year immune response data from
March 31, 2021	EX-4.2	Description of the Registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 to Form 10-K filed on March 31, 2021). Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Greenwich LifeSciences, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (i) common stock, $0.001 par value per share (?Common Stock?). Unless the context otherwi
March 31, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39555 GREENWICH LIF
March 8, 2021	424B3	561,798 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-238829 PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus dated September 24, 2020) 561,798 Shares of Common Stock This Prospectus Supplement No. 2 amends and supplements information contained in that certain Prospectus, dated September 24, 2020 (the ?Prospectus?), as amended, relating to the resale by certain selling stockholders listed in the section
December 22, 2020	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 17, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
December 22, 2020	EX-1.1	Underwriting Agreement, dated December 17, 2020 Exhibit 1.1 GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT 660,000 Shares of Common Stock December 17, 2020 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, NY 10019 As Representative of the Several Underwriters Named on Schedule I hereto Ladies and Gentlemen: GREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated
December 22, 2020	EX-99.2	Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock Exhibit 99.2 December 22, 2020 Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock STAFFORD, Texas—(Business Wire)— Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today anno
December 22, 2020	EX-99.1	Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock Exhibit 99.1 December 18, 2020 Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock STAFFORD, Texas—(Business Wire)— Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, to
December 18, 2020	424B4	660,000 Shares Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-251366 PROSPECTUS 660,000 Shares Common Stock We are offering 660,000 shares of our common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “GLSI.” We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced p
December 17, 2020	S-1MEF	- As filed with the U.S. Securities and Exchange Commission on December 17, 2020 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GREENWICH LIFESCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-5473709 (State or other jurisdiction of incorporati
December 16, 2020	FWP	FWP
December 15, 2020	8-K	Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
December 15, 2020	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT Shares of Common Stock , 2020 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, NY 10019 As Representative of the Several Underwriters Named on Schedule I hereto Ladies and Gentlemen: GREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue a
December 15, 2020	CORRESP	December 15, 2020 December 15, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
December 15, 2020	CORRESP	Greenwich LifeSciences, Inc. 3992 Bluebonnet Dr, Building 14 Stafford, TX 77477 Greenwich LifeSciences, Inc. 3992 Bluebonnet Dr, Building 14 Stafford, TX 77477 December 15, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Re: Greenwich LifeSciences, Inc. (CIK: 0001799788) Registration Statement on Form S-1 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the
December 15, 2020	S-1	Registration Statement - As filed with the U.S. Securities and Exchange Commission on December 15, 2020 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GREENWICH LIFESCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-5473709 (State or other jurisdiction of incorporati
December 15, 2020	EX-99.1	Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates Exhibit 99.1 December 15, 2020 Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates STAFFORD, Texas—(Business Wire)— Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone sur
December 14, 2020	8-K	Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
December 14, 2020	EX-99.1	Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer Exhibit 99.1 December 11, 2020 Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer ‒ The GP2 Phase III clinical trial design was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) and introduced by the Global Principal Investigator, Professor Mothaffar F. Rimawi of Baylor College of Medicine ‒ In the Phase I
December 10, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 9, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commi
December 10, 2020	EX-99.1	Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer Exhibit 99.1 December 9, 2020 Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer ? Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today ? Phase IIb clinical trial was a prospective, randomized, single-blinded, placeb
December 7, 2020	DRS	- As confidentially submitted to the U.S. Securities and Exchange Commission on December 7, 2020 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GREENWICH LIFESCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-5473709 (State or other jurisdictio
November 30, 2020	SC 13D	GLSI / Greenwich LifeSciences, Inc. / McWilliams David Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Greenwich LifeSciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 396879108 (CUSIP Number) David McWilliams 3992 Bluebonnet Dr., Building 14 Stafford, TX 77477 Telephone: (832) 819-3232 (Name, Address and Telephone Number
November 24, 2020	EX-99.1	Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer Exhibit 99.1 November 23, 2020 Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer ‒ Phase III clinical trial to be led by Baylor College of Medicine ‒ In the Phase IIb clinical trial, led by MD Anderson, no recurrences were observed in the HER2/neu 3+ adjuvant setting after
November 24, 2020	8-K	Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 23, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
November 19, 2020	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
November 19, 2020	EX-99.1	Greenwich LifeSciences, Inc. Corporate Presentation Exhibit 99.1
November 19, 2020	EX-99.2	Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2, Its Lead Drug Candidate for the Prevention of Recurring Breast Cancer Exhibit 99.2 November 18, 2020 Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2, Its Lead Drug Candidate for the Prevention of Recurring Breast Cancer ‒ Company now preparing to enter a phase III clinical trial ‒ Phase IIb clinical trial was a prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites) trial led by MD Anderson
November 16, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39555 G
November 13, 2020	8-K	Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Comm
November 13, 2020	EX-99.1	Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial Exhibit 99.1 Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial STAFFORD, Texas—(BUSINESS WIRE)— Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously under
November 10, 2020	424B3	1,685,394 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-238829 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated September 24, 2020) 1,685,394 Shares of Common Stock This Prospectus Supplement No. 1 amends and supplements information contained in that certain Prospectus, dated September 24, 2020 (the ?Prospectus?) relating to the resale by certain selling stockholders listed in the section of the Pro
October 13, 2020	SC 13D	GLSI / Greenwich LifeSciences, Inc. / Patel Kinnary Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Greenwich LifeSciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 396879108 (CUSIP Number) Snehal Patel 3992 Bluebonnet Dr., Building 14 Stafford, TX 77477 Telephone: (832) 819-3232 (Name, Address and Telephone Number of
October 13, 2020	EX-99.1	Joint Filing Agreement among Snehal Patel, Snehal Patel IRA, Kinnary Patel IRA, Patel Family Trust 1, Patel Family Trust 2 and Patel Family Trust 3 Exhibit 99.1 AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of Greenwich LifeSciences, Inc., a Delaware corp
October 9, 2020	EX-99.1	Greenwich LifeSciences, Inc. Corporate Presentation Exhibit 99.1
October 9, 2020	EX-99.4	Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts at Upcoming Major Breast Cancer Conference Exhibit 99.4 Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts at Upcoming Major Breast Cancer Conference STAFFORD, TX / [Business Wire] / October 8, 2020 / Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously u
October 9, 2020	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 6, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Commis
October 9, 2020	EX-99.2	Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial Exhibit 99.2 Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial STAFFORD, TX / [Business Wire] / October 6, 2020 / Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previo
October 9, 2020	EX-99.3	Greenwich LifeSciences, Inc. to Participate at Upcoming Investor and Partnering Conferences Exhibit 99.3 Greenwich LifeSciences, Inc. to Participate at Upcoming Investor and Partnering Conferences STAFFORD, TX / [Business Wire] / October 7, 2020 / Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery,
October 1, 2020	EX-3.2	Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Form 8-K filed on October 1, 2020) Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS of Greenwich LifeSciences, Inc. PREAMBLE These Second Amended and Restated By-laws (these “By-laws”) are subject to, and governed by, the Delaware General Corporation Law (the “DGCL”) and the Second Amended and Restated Certificate of Incorporation (the “Certificate”) of Greenwich LifeSciences, Inc., a Delaware corporation (the “Corporation”). In the
October 1, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 29, 2020 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39555 20-5473709 (State or other jurisdiction of incorporation) (Com
October 1, 2020	EX-99.1	Greenwich LifeSciences, Inc. Announces Pricing of Initial Public Offering Exhibit 99.1 Greenwich LifeSciences, Inc. Announces Pricing of Initial Public Offering STAFFORD, TX / [Business Wire] / September 24, 2020 / Greenwich LifeSciences, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the pricing of
October 1, 2020	EX-3.1	Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on October 1, 2020) Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 05:23 PM 09/29/2020 FILED 05:23 PM 09/29/2020 SR 20207548835 - File Number 4211497 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GREENWICH LIFESCIENCES, INC. GREENWICH LIFESCIENCES, INC. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delawar
October 1, 2020	EX-10.1	Employment Agreement between the Company and Snehal Patel dated September 29, 2020 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 1, 2020) Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into effective as of September 29, 2020 (the “Effective Date”), by and between Snehal Patel (the “Executive”) and Greenwich Lifesciences, Inc., a Delaware corporation (the “Company”). R E C I T A L S Whereas, the parties wish to enter into an employment agreement between the Execut
October 1, 2020	EX-99.2	Greenwich LifeSciences, Inc. Announces Closing of Initial Public Offering Exhibit 99.2 Greenwich LifeSciences, Inc. Announces Closing of Initial Public Offering STAFFORD, TX / [Business Wire] / September 29, 2020 / Greenwich LifeSciences, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the closing of
September 28, 2020	424B4	1,685,394 Shares of Common Stock PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-238829 1,685,394 Shares of Common Stock The selling stockholders plan to sell an aggregate of up to 1,685,394 shares of common stock. The selling stockholders must sell their shares at a fixed price per share of $5.75, which is the per share price of the shares being offered in our initial public offering, until such time as our shar
September 28, 2020	EX-99.1	Greenwich LifeSciences, Inc. Announces Pricing of Initial Public Offering Exhibit 99.1 Greenwich LifeSciences, Inc. Announces Pricing of Initial Public Offering STAFFORD, TX / [Business Wire] / September 24, 2020 / Greenwich LifeSciences, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the pricing of
September 28, 2020	EX-1.1	Underwriting Agreement, dated September 24, 2020 Exhibit 1.1 GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT 1,260,870 Shares of Common Stock September 24, 2020 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, NY 10019 As Representative of the Several Underwriters Named on Schedule I hereto Ladies and Gentlemen: GREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions sta
September 28, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 Greenwich LifeSciences, Inc.
September 28, 2020	424B4	1,260,870 Shares Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-238829 1,260,870 Shares Common Stock This is the initial public offering of shares of common stock of Greenwich LifeSciences, Inc. We are offering 1,260,870 shares of our common stock. No public market currently exists for our stock. The initial public offering price is $5.75 per share. Our common stock has been approved for listing
September 23, 2020	8-A12B	Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Greenwich LifeSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5473709 (State or other jurisdiction of incorporation or organization (I.R.S. Employer Identification
September 22, 2020	CORRESP	- September 22, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
September 22, 2020	FWP	Greenwich LifeSciences Investor Presentation September 2020 Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 22, 2020 Relating to the Preliminary Prospectus dated September 8, 2020 Registration S Greenwich LifeSciences Investor Presentation September 2020 Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 22, 2020 Relating to the Preliminary Prospectus dated September 8, 2020 Registration Statement File No.
September 22, 2020	CORRESP	- GREENWICH LIFESCIENCES, INC. 3992 Bluebonnet Dr, Building 14 Stafford, TX 77477 September 22, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Jenn Do Terence O’Brien David Gessert Michael Clampitt Re: Greenwich LifeSciences, Inc. Registration Statement on Form S-1, as amended File No. 333-238829 Ladies and Gentlemen: Pursuant to Rul
September 10, 2020	S-1/A	- AMENDMENT NO. 4 TO FORM S-1 As filed with the Securities and Exchange Commission on September 10, 2020 Registration Statement No.
September 9, 2020	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT Shares of Common Stock , 2020 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, NY 10019 As Representative of the Several Underwriters Named on Schedule I hereto Ladies and Gentlemen: GREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue a
September 9, 2020	S-1/A	- AMENDMENT NO. 3 TO FORM S-1 As filed with the Securities and Exchange Commission on September 8, 2020 Registration Statement No.
June 26, 2020	CORRESP	- GREENWICH LIFESCIENCES, INC. 3992 Bluebonnet Dr, Building 14 Stafford, TX 77477 June 26, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Jenn Do Terence O’Brien David Gessert Michael Clampitt Re: Greenwich LifeSciences, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed June 23, 2020 File No. 333-238829 Dear Ladies and
June 26, 2020	S-1/A	- AMENDMENT NO. 2 REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on June 26, 2020 Registration Statement No.
June 23, 2020	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT Shares of Common Stock , 2020 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, NY 10019 As Representative of the Several Underwriters Named on Schedule I hereto Ladies and Gentlemen: GREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue a
June 23, 2020	EX-3.4	Form of Second Amended and Restated Certificate of Incorporation, to be effective immediately prior to the closing of this offering Exhibit 3.4 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GREENWICH LIFESCIENCES, INC. GREENWICH LIFESCIENCES, INC. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify as follows: A. The name of the Corporation is Greenwich LifeSciences, Inc. B. The original Certificate of Incorporation of the Corpo
June 23, 2020	S-1/A	- REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on June 22, 2020 Registration Statement No.
June 23, 2020	EX-4.2	Form of Underwriter Warrant (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to Form S-1 filed on June 23, 2020) Exhibit 4.2 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE LATER OF THE EF
June 23, 2020	EX-10.3	Exclusive License Agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the Company (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to Form S-1 filed on June 23, 2020) Exhibit 10.3 EXCLUSIVE LICENSE AGREEMENT BETWEEN THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. AND NORWELL, INC. THIS EXCLUSIVE LICENSE AGREEMENT is entered into as of the 24th day of April, 2009 (the “Effective Date”), by and between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., a tax-exempt corporation organized under the laws of
June 23, 2020	EX-10.5	Second Amendment to Exclusive License Agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the Company (incorporated by reference to Exhibit 10.5 to Amendment No. 1 to Form S-1 filed on June 23, 2020) Exhibit 10.5
June 23, 2020	FWP	Greenwich LifeSciences Investor Presentation June 2020 Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated June 22, 2020 Relating to the Preliminary Prospectus dated June 22, 2020 Registration Statement File Greenwich LifeSciences Investor Presentation June 2020 Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated June 22, 2020 Relating to the Preliminary Prospectus dated June 22, 2020 Registration Statement File No.
June 23, 2020	EX-10.7	Form of Employment Agreement between the Company and Snehal Patel, to be effective on the closing of the offering contemplated by this registration statement Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into effective as of , 2020 (the “Effective Date”), by and between Snehal Patel (the “Executive”) and Greenwich Lifesciences, Inc., a Delaware corporation (the “Company”). R E C I T A L S Whereas, the parties wish to enter into an employment agreement between the Executive and the
June 23, 2020	EX-4.1	Specimen Stock Certificate evidencing the shares of common stock (Incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1 filed on June 23, 2020) Exhibit 4.1
June 23, 2020	EX-3.7	Amendment to Amended and Restated Certificate of Incorporation dated June 22, 2020 Exhibit 3.7 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Greenwich LifeSciences, Inc. Under Section 242 of the Delaware General Corporation Law Greenwich LifeSciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”) hereby certifies as follows: FIRST: The Amended and Restated Certificate of Incorporation of
June 23, 2020	EX-10.8	Registration Rights Agreement (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to Form S-1 filed on June 23, 2020) Exhibit 10.8 Registration Rights Agreement This Registration Rights (this “Agreement”) is made and entered into as of July 23, 2010 (the “Effective Date”) by and among Norwell, Inc., a Delaware corporation (the “Company”) and the holders of Series A Preferred Stock (the “Series A Preferred Stock”) as set forth on Exhibit A hereto (the “Holders” or the “Investors”). RECITALS A. The Company and the
June 23, 2020	EX-10.6	American Arbitration Association Award of Arbitrators (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to Form S-1 filed on June 23, 2020) Exhibit 10.6
June 23, 2020	EX-3.6	Form of Second Amended and Restated Bylaws, to be effective immediately prior to the closing of this offering Exhibit 3.6 SECOND AMENDED AND RESTATED BY-LAWS of Greenwich LifeSciences, Inc. PREAMBLE These Second Amended and Restated By-laws (these “By-laws”) are subject to, and governed by, the Delaware General Corporation Law (the “DGCL”) and the Second Amended and Restated Certificate of Incorporation (the “Certificate”) of Greenwich LifeSciences, Inc., a Delaware corporation (the “Corporation”). In the
June 23, 2020	EX-10.4	First Amendment to Exclusive License Agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the Company (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to Form S-1 filed on June 23, 2020) Exhibit 10.4
June 22, 2020	CORRESP	- GREENWICH LIFESCIENCES, INC. 3992 Bluebonnet Dr, Building 14 Stafford, TX 77477 June 22, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Jenn Do Terence O’Brien David Gessert Michael Clampitt Re: Greenwich LifeSciences, Inc. Registration Statement on Form S-1 Filed May 29, 2020 File No. 333-238829 Dear Ladies and Gentlemen: This let
May 29, 2020	EX-3.5	Amended and Restated Bylaws, currently in effect Exhibit 3.5 NORWELL, INC. AMENDED AND RESTATED BYLAWS July 23, 2010 TABLE OF CONTENTS Page ARTICLE I-CORPORATE OFFICES 4 1.1 Registered Office 4 1.2 Other Offices 4 ARTICLE II-MEETINGS OF STOCKHOLDERS 4 2.1 Place of Meetings 4 2.2 Annual Meeting 4 2.3 Special Meetings 4 2.4 Notice of Stockholders’ Meetings 4 2.5 Manner of Giving Notice; Affidavit of Notice 5 2.6 Quorum 5 2.7 Adjourned Meeting; Not
May 29, 2020	CORRESP	- GREENWICH LIFESCIENCES, INC. 3992 Bluebonnet Dr, Building 14 Stafford, TX 77477 May 29, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Jenn Do Terence O’Brien David Gessert Michael Clampitt Re: Greenwich LifeSciences, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted April 7, 2020 CIK No. 0001799788 Dear La
May 29, 2020	S-1	Power of Attorney As filed with the Securities and Exchange Commission on May 29, 2020 Registration Statement No.
May 29, 2020	EX-3.1	Amended and Restated Certificate of Incorporation, currently in effect Exhibit 3.1
May 29, 2020	EX-10.1	2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Form S-1 filed on May 29, 2020) Exhibit 10.1 GREENWICH LIFE SCIENCES, INC. 2019 EQUITY INCENTIVE PLAN EFFECTIVE AS OF SEPTEMBER 30, 2019 GREENWICH LIFE SCIENCES, INC. 2019 EQUITY INCENTIVE PLAN EFFECTIVE AS OF SEPTEMBER 30, 2019 SECTION 1. INTRODUCTION. The Company’s Board of Directors adopted the Greenwich Life Sciences, Inc. 2019 Equity Incentive Plan effective as of the Adoption Date subject to obtaining Company stockholder a
May 29, 2020	EX-3.3	Amendment to Amended and Restated Certificate of Incorporation dated September 9, 2019 Exhibit 3.3
May 29, 2020	EX-3.2	Amendment to Amended and Restated Certificate of Incorporation dated March 2, 2018 Exhibit 3.2
May 29, 2020	EX-10.2	Form of Indemnification Agreement with directors and executive officers (incorporated by reference to Exhibit 10.1 to Form S-1 filed on May 29, 2020) Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , between Greenwich LifeSciences, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers, managers, or in other capacities unless they are provided
April 7, 2020	DRSLTR	- GREENWICH LIFESCIENCES, INC. 2311 Spartan Trail Sugar Land, TX 77479 April 7, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Jenn Do Terence O’Brien David Gessert Michael Clampitt Re: Greenwich LifeSciences, Inc. Draft Registration Statement on Form S-1 Submitted January 28, 2020 CIK No. 0001799788 Dear Ladies and Gentlemen: This l
April 7, 2020	DRS/A	- As confidentially submitted to the U.S. Securities and Exchange Commission on April 7, 2020, pursuant to Section 6(e) of the Securities Act of 1933, as amended, as Amendment No. 1 to the draft registration statement. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GREENWICH LIFE
January 28, 2020	DRS	- As confidentially submitted to the U.S. Securities and Exchange Commission on January 27, 2020 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GREENWICH LIFESCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-5473709 (State or other jurisdictio
January 27, 2020	DRSLTR	- Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.

GLSI / Greenwich LifeSciences, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)